O's-PNI may represent a useful indicator of the occurrence of complications and length of hospital stay, and may influence overall survival at 6 mo postsurgery. Nutritional management during the perioperative period could therefore contribute to satisfactory outcomes following esophagectomy in esophageal cancer patients.
Electrogastrography (EGG) is a non-invasive diagnostic motility for recording gastric
myoelectrical activity. Gastric myoelectrical activity was first recorded in 1922.
Advances in recording equipment enabled widespread use of cutaneous EGG after 1985. Later,
introduction of multichannel EGG (M-EGG) enabled measurement of electrical activity
transmission. At present, M-EGG findings are used as objective indicators of gastric
motility disorders caused by various diseases. EGG measures two categories of gastric
electrical activity: electrical response activity, or spike potentials; and electrical
control activity, or slow waves. The appearance of abnormal rhythmic electrical activity
is indicative of abnormalities in gastric motility. The normal frequency range of gastric
electrical activity (normogastria) is around 3 cycles per min. Multiple EGG parameters
assist in the assessment of gastric myoelectrical activity, and significant correlations
between EGG and other gastric motility tests have been demonstrated in many studies. In
Japan, however, EGG remains in the exploratory stage, and its clinical use is limited.
There are large variations in procedures and systems used in previous studies, thus there
is a need for standardization of EGG procedures and technical terminology. Here, we
outline the current status of EGG and report the M-EGG procedures used in our department
in addition to our M-EGG findings.The abstract of this manuscript was presented
during an educational seminar titled "Current status of gastrointestinal motility tests
and keys for immediate implementation" at the 54th Annual Meeting of the Japan Society of
Smooth Muscle Research
Aims: To determine the relation between clinical outcome and tumour grade defined by a MIB-1 (Ki-67) score based grading system. Method: The clinical and pathological features of 50 patients with myxoid liposarcoma were evaluated, and MIB-1 immunostaining was performed to grade these patients' tumours. Univariate and multivariate analyses were conducted to evaluate survival. Clinical follow up details were available for all patients (median, 46.5 months; range, 9-408).Results: Univariate analysis revealed that the tumour site (p < 0.05), round cell component content (p < 0.01), necrosis (p < 0.01), mitosis (p < 0.01), MIB-1 labelling index (p < 0.001), and tumour grade (p < 0.001) had a significant impact on overall survival. Multivariate analysis showed that, of the variables evaluated, the tumour grade defined by a MIB-1 score based grading system was the most significant adverse prognostic factor. Conclusion: Tumour grade determined by the grading system using the MIB-1 score (MIB-1 system) is a very strong prognostic factor in patients with myxoid liposarcoma.M yxoid and round cell liposarcomas are regarded as belonging to a continuous histopathological spectrum characteristic of a chromosome translocation, t(12;16)(q13;p11), resulting in the fusion of the TLS and CHOP genes.1-5 These tumours show a variable clinical behaviour, with round cell liposarcomas being highly metastatic, poorly differentiated tumours, whereas myxoid liposarcomas are less metastatic, moderately and well differentiated tumours, and are associated with a more favourable survival rate.6-9 Diagnosis and, hence, prognostic predictions can be complicated by lesions that often contain admixed components with myxoid and round cell morphologies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.